Generic
Lenograstrim
1 brands available in the market
At a glance
Lenograstrim is used to prevent infections after chemotherapy. It is a growth factor that stimulates the bone marrow to produce white blood cells, which protect the body against infections.
Description
Lenograstrim (rHuG-CSF) belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. rHuG-CSF is a factor which stimulates the neutrophil precursor cells as demonstrated by CFU-S and CFU-GM cell count increases in peripheral blood. It reduces the duration and severity of neutropenia after chemotherapy or bone marrow transplantation.
Indications
- Prevention of infections after chemotherapy (neutropenia)
- Neutropenia following bone marrow transplantation
- Mobilization of PBPC for autologous peripheral blood stem cell transplantation
Therapeutic class
Haematopoietic Agents
Pharmacological class
Granulocyte Colony Stimulating Factor (G-CSF)
Pharmacology
Lenograstrim is recombinant human G-CSF that stimulates neutrophil production and release. It increases CFU-S and CFU-GM cell counts and reduces the duration of neutropenia.
Mechanism of action
Stimulates neutrophil precursor cells and increases CFU-S and CFU-GM cell counts in peripheral blood.
Dosage
Adult Dose:
- Post-BMT: 19.2 million IU/m² or 150 mcg/m² IV infusion daily, starting the day after transplantation for a maximum of 28 days
- PBPC Mobilization (Monotherapy): 1.28 million IU/kg or 10 mcg/kg SC daily for 4-6 days
- Chemotherapy-induced Neutropenia: 19.2 million IU/m² or 150 mcg/m² daily, starting the day after chemotherapy for a maximum of 28 days
Children (>2 years): 19.2 million IU/m² or 150 mcg/m² daily, starting the day after transplantation for a maximum of 28 days
Administration
- Your doctor or nurse will give this medicine; do not self-administer
- Given as subcutaneous (SC) or intravenous (IV) injection
- Leave syringe at room temperature for 30 minutes before use (for more comfortable injection)
Missed dose
If you miss a dose, please consult your doctor.
Side effects
Common Side Effects:
- Bone pain
- Weakness
- Increased white blood cell count
- Low blood platelets
- Back pain
- Increased liver enzymes
- Headache
- Pain or redness at injection site
Precautions & warnings
- First dose should be given at least 24 hours after chemotherapy or BMT
- Store in refrigerator, protect from light, do not shake
- Inform your doctor if you notice a lump, swelling, or bruising at injection site
- Inform your doctor if you have fever, shortness of breath, or trouble breathing
- Caution when driving or doing activities requiring concentration (may cause dizziness)
Contraindications
- Bone marrow cancer
- Children less than 2 years
- Hypersensitivity to the drug
Drug interactions
- Increased risk of myelosuppression with myelosuppressive antineoplastic agents
- Increased pulmonary toxicity with bleomycin and cyclophosphamide
Food interactions
Safety with alcohol is not known; consult your doctor.
Use in pregnancy
Use in Pregnancy: Lenograstrim is unsafe during pregnancy; definite evidence of risk to the developing baby. Use only in life-threatening situations with doctor's advice.
Use in lactation
Use in Lactation: Lenograstrim is probably safe during breastfeeding. Limited human data suggests no significant risk to the baby.
Pediatric use
Dose established for children over 2 years; safety not established in children under 2 years.
Geriatric use
No special studies in elderly; use with caution.
Renal / hepatic impairment
Renal Impairment: Limited information available; consult your doctor.
Hepatic Impairment: Limited information available; consult your doctor.
Overdose effects
No specific overdose information available; symptomatic and supportive measures should be employed.
Storage conditions
Store in refrigerator; protect from light; keep out of reach of children.
Chemical structure
Lenograstrim